Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CASIMERSEN vs CASIRIVIMAB\IMDEVIMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CASIMERSEN vs CASIRIVIMAB\IMDEVIMAB: Safety Overview

Metric CASIMERSEN CASIRIVIMAB\IMDEVIMAB
Total FAERS Reports 767 4,248
Deaths Reported 7 137
Death Rate 0.9% 3.2%
Hospitalizations 87 1,351
Average Patient Age 14.0 yrs 54.3 yrs
% Female Patients 0.4% 55.4%
FDA Approval Date Feb 25, 2021 N/A
Manufacturer Sarepta Therapeutics, Inc. N/A
Marketing Status Prescription N/A